Eriguchi M, Mathé G
Biomed Pharmacother. 1986;40(4):143-7.
Two mathematical models were presented to approximate the various survival curves for malignant diseases. The models individualized several segments in the survival curve. Also, the hazard function of the curve and the confidence intervals of the curve could be calculated. First, we studied the survival-after-relapse curve for adjuvant therapy of malignant melanoma. The curve for chemoimmunotherapy had three segments and the curve for immunotherapy, two segments. The immunotherapy showed its effect in the early period of treatment. Second, the disease-free survival curves for adjuvant therapies of breast cancer were compared; Oncofrance trial: a combination of AVCF was superior to a combination of CMF in all the periods of the therapy; Lacour's trial: Poly A-Poly U was more effective than the control in the middle and late period; Bonadonna's trial: CMF was superior to the control in the early period. Third, the survival curves for adjuvant therapy of stomach cancer; immunotherapy versus non-immunotherapy were analysed. Comparison of the confidence intervals of each curve clarified that no significant difference could be found between them. Thus, these analyses showed the effectiveness of the compared adjuvant treatments.
提出了两种数学模型来近似恶性疾病的各种生存曲线。这些模型将生存曲线分为几个部分。此外，还可以计算曲线的风险函数和置信区间。首先，我们研究了恶性黑色素瘤辅助治疗的复发后生存曲线。化学免疫疗法的曲线有三个部分，免疫疗法的曲线有两个部分。免疫疗法在治疗早期显示出效果。其次，比较了乳腺癌辅助治疗的无病生存曲线；Oncofrance试验：在治疗的所有阶段，AVCF联合用药优于CMF联合用药；Lacour试验：聚A-聚U在治疗中期和后期比对照组更有效；Bonadonna试验：CMF在治疗早期优于对照组。第三，分析了胃癌辅助治疗的生存曲线；免疫疗法与非免疫疗法。对每条曲线的置信区间进行比较后发现，两者之间没有显著差异。因此，这些分析表明了所比较的辅助治疗的有效性。
